Combined Acamprosate and Naltrexone, with Cognitive Behavioural Therapy is Superior to Either Medication Alone for Alcohol Abstinence: A Single Centres' Experience with Pharmacotherapy

Connor, Jason, Feeney, Gerald, McPherson, Anne, Tucker, Jane, & Young, Ross (2006) Combined Acamprosate and Naltrexone, with Cognitive Behavioural Therapy is Superior to Either Medication Alone for Alcohol Abstinence: A Single Centres' Experience with Pharmacotherapy. Alcohol and Alcoholism, 41(3), pp. 321-327.

View at publisher (open access)

Abstract

Aims: To compare treatment outcomes amongst patients offered pharmacotherapy with either naltrexone or acamprosate used singly or in combination, in a 12-week outpatient cognitive behavioural therapy (CBT) programme for alcohol dependence. Methods: We matched 236 patients across gender, age group, prior alcohol detoxification, and dependence severity and conducted a cohort comparison study of three medication groups (CBT+acamprosate, CBT+naltrexone, CBT+combined medication) which included 59 patients per group. Outcome measures included programme attendance, programme abstinence and for those who relapsed, cumulative abstinence duration (CAD) and days to first breach (DFB). Secondary analyses compared the remaining matched 59 subjects who declined medication with the pharmacotherapy groups. Results: Across medication groups, CBT+ combined medication produced the greatest improvement across all outcome measures. Although a trend favoured the CBT+ combined group, differences did not reach statistical significance. Programme attendance: CBT + Acamprosate group (66.1%), CBT + Naltrexone group (79.7%), and in the CBT + Combined group (83.1%). Abstinence rates were 50.8, 66.1, and 67.8%, respectively. For those that did not complete the programme abstinent, the average number of days abstinent (CAD) were 45.07, 49.95, and 53.58 days, respectively. The average numbers of days to first breach (DFB) was 26.79, 26.7, and 37.32 days. When the focal group (CBT + combined) was compared with patients who declined medication (CBT-alone), significant differences were observed across all outcome indices. Withdrawal due to adverse medication effects was minimal. Conclusions: The addition of both medications (naltrexone and acamprosate) resulted in measurable benefit and was well tolerated. In this patient population naltrexone with CBT is as effective as combined medication with CBT, but the trend favours combination medication.

Impact and interest:

39 citations in Scopus
Search Google Scholar™
35 citations in Web of Science®

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

ID Code: 21799
Item Type: Journal Article
Additional Information: Articles free to read on journal website after 12 months
Keywords: Naltrexone, Acamprosate, Alcohol Dependence
DOI: 10.1093/alcalc/agl007
ISSN: 0735-0414
Subjects: Australian and New Zealand Standard Research Classification > PSYCHOLOGY AND COGNITIVE SCIENCES (170000) > PSYCHOLOGY (170100) > Health Clinical and Counselling Psychology (170106)
Divisions: Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
Deposited On: 17 Jun 2009 12:58
Last Modified: 22 Jan 2015 01:51

Export: EndNote | Dublin Core | BibTeX

Repository Staff Only: item control page